is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112. 

Current Cases

Bellicum Pharmaceuticals, Inc. [NASDAQ: BLCM]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Bellicum Pharmaceuticals, Inc.

Oklahoma City, OK (February 12, 2018) – On February 6, 2018, a securities class action lawsuit was filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is May 8, 2017 through January 30, 2018. More specifically, this litigation was filed because of materially false and/or misleading statements and/or failure to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with Bellicum’s lead product candidate, BPX-501; and (2) as a result, Bellicum’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On this news, the Company's share price fell from $8.20 per share on January 30, 2018 to a closing price of $6.08 on January 31, 2018—a $2.12 or a 25.85% drop.

Plaintiff seeks to recover damages on behalf of all Bellicum Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, April 9, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.